Johnson & Johnson’s Janssen Pharmaceutical announced that the European Commission has granted marketing authorization for Akeega in the form of a dual action tablet, given with prednisone or prednisolone, for the treatment of adults with metastatic castration-resistant prostate cancer and BRCA1/2 mutations in whom chemotherapy is not clinically indicated.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on JNJ:
